Comment on Peer Reviewed Discussion: Healthcare and Research

This assignment presents a student's response to a peer-reviewed discussion on healthcare topics. The student comments on the provided information, specifically addressing the use of Amlodipine in managing atherosclerosis and the discontinuation of beta-blockers. The student also discusses the use of carvedilol in CKD patients. The student also reviews another response and comments on the treatment plan, focusing on the use of Ranexa for angina and the use of glizipide and amlodipine, while expressing concerns about the use of Metformin. The assignment includes citations of relevant research papers.

Running head: COMMENT ON PEER REVIEWED DISCUSSION
Name of the student
University name
Author’s note

1
COMMENT ON PEER REVIEWED DISCUSSION
Response to post 1:
Dear friend, I have read your response and I have found this piece of information very
useful. I found the administration of Amlodipine very useful in checking the progression of
atherosclerosis within the patient. However I would like to slightly contradict with the point
of discontinuation of the beta blockers. Beta blockers have more side effects than positive
effects on the overall health of the patient with hypertension and chronic kidney disease.
However, I would beg to differ owing to some facts as supported through evidence based
studies. Studies with some of the beta blockers such as carvedilol have indicated attenuated
increase in albumineria and as well as reduction in cardiovascular events in CKD patients
with hypertension (Stone et al., 2014). Though, aspirin has been effectively used for the
prevention of myocardial infarction in excess amounts it can lead to symptomatic expression
of CKD.
Response to post 2:
Dear friend, I have gone through your response and found the treatment plan adopted
by you to be every effective. For example, the use of Ranexa for the control of angina realted
pain in the patient has been found to be very effective. I also appreciate the use of glizipide
and amlodipine as they are easily metabolized in the liver and would not be a risk factor for
the ones with chronic kidney diseases. However, I am slightly sceptical regarding the use of
Metformin in the patient as the exclusion of the drug is heavily dependent upon the function
of the kidney. As commented by Toblli, Di Gennaro & Rivas (2015), overdose of the
antihypertensive can also affect the functioning of the kidney in the patient.

2
COMMENT ON PEER REVIEWED DISCUSSION
References
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Merz, C. N. B., Blum, C. B., Eckel, R.
H., ... & McBride, P. (2014). 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the
American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Journal of the American College of Cardiology, 63(25 Part B), 2889-
2934.
Toblli, J. E., Di Gennaro, F., & Rivas, C. (2015). Changes in echocardiographic parameters in
iron deficiency patients with heart failure and chronic kidney disease treated with
intravenous iron. Heart, Lung and Circulation, 24(7), 686-695.